Abbott announces FDA approved IDE for Coronary IVL system
Abbott (ABT) announced that the U.S. Food and Drug Administration, FDA, has approved an investigational device exemption, IDE, for its Coronary ...
Medical Device Network on MSN1d
Abbott eyes intravascular lithotripsy market with clinical trial approval
The US Food and Drug Administration (FDA) has granted Abbott an investigational device exemption to evaluate the company’s ...
Zacks Investment Research on MSN1d
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
Abbott ABT has received the FDA’s investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (“IVL”) system to evaluate the treatment of severe calcification in coronary ...
Crain's Chicago Business2d
Abbott gets green light for clinical trials of new heart treatment system
Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...
Fierce Biotech2d
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries
Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...